Update date
30 Jun 2025
Shareable Research Card
IMRN - Immuron Ltd Research And Development Expense
This metric view shows IMRN - Immuron Ltd research and development expense history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: 2025
- Latest reported value
- A$3,597,296
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 30 Jun 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: 2025.
- Latest reported value on this page: A$3,597,296.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Research And Development Expense
Latest reported research and development expense: A$3,597,296. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
2025
SEC-backed company facts were refreshed from filings filed on 25 Sep 2025.
Benchmark Context
How Research And Development Expense compares with peers
Immuron Ltd sits in the lower half of the current research and development expense sample.
Compared with
Compared with 12 companies reporting research and development expense in AUD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0.2x the current sample midpoint. Research And Development Expense is down about 33% versus the comparable prior period.
- Visible rows currently span reported period ends from 30 Jun 2019 to 30 Jun 2025.
- Nearby companies in this sample: NOVONIX Ltd and Mobilicom Ltd.
- Current sample position: rank #9 of 12 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Immuron Ltd: Research And Development Expense
Latest period: 2025. Period end: 30 Jun 2025. Units: AUD. Frequency: annual.
Research And Development Expense is an SEC-reported metric from company XBRL facts.
Metric Snapshot
- Latest value
- A$3,597,296
- Coverage range
- 30 Jun 2016 - 30 Jun 2025
- Fact rows
- 10
What This Metric Tells You
- Shows the reported level of research and development expense over 30 Jun 2016 - 30 Jun 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 10 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use annual sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare This Metric Across Companies
Compare latest available Research And Development Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Immuron Ltd appears at rank #9 in the latest comparison sample.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | Telix Pharmaceuticals Ltd (tlx) | A$194,637,000 | Year - 31 Dec 2024 | Open Telix Pharmaceuticals Ltd Research And Development Expense |
| 2 | IMMUTEP Ltd (immp) | A$49,778,916 | Year - 30 Jun 2025 | Open IMMUTEP Ltd Research And Development Expense |
| 3 | Carbon Revolution Public Ltd Co (crevf) | A$36,102,000 | Year - 30 Jun 2024 | Open Carbon Revolution Public Ltd Co Research And Development Expense |
| 4 | Neuphoria Therapeutics Inc. (neup) | A$19,613,270 | Year - 30 Jun 2023 | Open Neuphoria Therapeutics Inc. Research And Development Expense |
| 5 | KAZIA THERAPEUTICS LTD (kzia) | A$17,380,000 | Year - 30 Jun 2024 | Open KAZIA THERAPEUTICS LTD Research And Development Expense |
| 6 | ALTERITY THERAPEUTICS LTD (athe) | A$14,404,282 | Year - 30 Jun 2025 | Open ALTERITY THERAPEUTICS LTD Research And Development Expense |
Metric Details
- Metric
- Research And Development Expense (ResearchAndDevelopmentExpense)
- Taxonomy
- ifrs-full
- Units tracked
- AUD
- Frequency coverage
- annual
- History range
- 30 Jun 2016 - 30 Jun 2025
- Facts on this page
- 10
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Research And Development Expense, Annual (AUD)
Research And Development Expense, YoY Annual Change (%)
Immuron Ltd Annual Research And Development Expense (AUD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | A$3,597,296 | -A$1,778,165 | -33% | 01 Jul 2024 | 30 Jun 2025 | 20-F | 25 Sep 2025 | 2025 | FY |
| 2024 | A$5,375,461 | +A$2,783,316 | +107% | 01 Jul 2023 | 30 Jun 2024 | 20-F | 25 Sep 2025 | 2025 | FY |
| 2023 | A$2,592,145 | +A$1,934,430 | +294% | 01 Jul 2022 | 30 Jun 2023 | 20-F | 25 Sep 2025 | 2025 | FY |
| 2022 | A$657,715 | -A$709,339 | -52% | 01 Jul 2021 | 30 Jun 2022 | 20-F | 01 Oct 2024 | 2024 | FY |
| 2021 | A$1,367,054 | +A$188,369 | +16% | 01 Jul 2020 | 30 Jun 2021 | 20-F | 28 Sep 2023 | 2023 | FY |
| 2020 | A$1,178,685 | +A$134,157 | +13% | 01 Jul 2019 | 30 Jun 2020 | 20-F | 09 Sep 2022 | 2022 | FY |
| 2019 | A$1,044,528 | -A$1,212,696 | -54% | 01 Jul 2018 | 30 Jun 2019 | 20-F | 29 Oct 2021 | 2021 | FY |
| 2018 | A$2,257,224 | -A$2,373,450 | -51% | 01 Jul 2017 | 30 Jun 2018 | 20-F | 28 Oct 2020 | 2020 | FY |
| 2017 | A$4,630,674 | +A$1,006,713 | +28% | 01 Jul 2016 | 30 Jun 2017 | 20-F | 28 Oct 2019 | 2019 | FY |
| 2016 | A$3,623,961 | 01 Jul 2015 | 30 Jun 2016 | 20-F | 31 Oct 2018 | 2018 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.